Jonsson Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.cancer.ucla.edu

Clinical Trials

Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation
Stage IVB Prostate Cancer AJCC v8
Metastatic Prostate Adenocarcinoma
Recurrent Prostate Carcinoma

Interventions: Drug: Abiraterone Acetate
Drug: Apalutamide
Drug: Leuprolide Acetate
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Radiation: Stereotactic Body Radiation Therapy

First Posted Date: 2019-04-04

Last Posted Date: 2025-01-28

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 28

Registration Number: NCT03902951

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Stereotactic Body Radiation Therapy Using HyperArc in Treating Patients With Recurrent Head and Neck Cancer

Not Applicable

Completed

Conditions: Recurrent Head and Neck Carcinoma

Interventions: Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Radiation: Stereotactic Body Radiation Therapy

First Posted Date: 2019-03-27

Last Posted Date: 2024-08-27

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 33

Registration Number: NCT03892720

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy

Phase 1

Suspended

Conditions: Stage IVB Lung Cancer AJCC v8
Extensive Stage Lung Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
Stage IVA Lung Cancer AJCC v8
Advanced Malignant Solid Neoplasm
Stage III Lung Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8
Stage IIIB Lung Cancer AJCC v8
Stage IIIC Lung Cancer AJCC v8

Interventions: Biological: Atezolizumab
Drug: Niraparib
Other: Questionnaire Administration
Other: Quality-of-Life Assessment
Drug: Temozolomide

First Posted Date: 2019-02-05

Last Posted Date: 2025-02-24

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 74

Registration Number: NCT03830918

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

CPX-351 Plus Enasidenib for Relapsed AML

Phase 2

Active, not recruiting

Conditions: Recurrent Acute Myeloid Leukemia

Interventions: Drug: Enasidenib Mesylate
Drug: Liposome-encapsulated Daunorubicin-Cytarabine

First Posted Date: 2019-01-31

Last Posted Date: 2023-09-28

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 2

Registration Number: NCT03825796

Locations: 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
University of California San Diego, San Diego, California, United States

Near-Infrared Image Guided Surgical Resection With Indocyanine Green in Treating Patients With Head and Neck Cancer

Phase 1

Withdrawn

Conditions: Head and Neck Carcinoma

Interventions: Procedure: Image-Guided Surgery
Drug: Indocyanine Green Drug

First Posted Date: 2018-11-19

Last Posted Date: 2022-03-17

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT03745690

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer

Phase 2

Active, not recruiting

Conditions: Recurrent Fallopian Tube Carcinoma
Recurrent Primary Peritoneal Carcinoma
Recurrent Ovarian Carcinoma

Interventions: Biological: Pembrolizumab

First Posted Date: 2018-11-07

Last Posted Date: 2024-04-15

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 5

Registration Number: NCT03732950

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma

Phase 2

Completed

Conditions: EGFR Gene Amplification
EGFR Gene Mutation
Glioblastoma
Recurrent Glioblastoma
Supratentorial Glioblastoma
TP53 Wt Allele

Interventions: Other: Fludeoxyglucose F-18
Drug: Osimertinib
Procedure: Positron Emission Tomography

First Posted Date: 2018-11-06

Last Posted Date: 2024-11-12

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 12

Registration Number: NCT03732352

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer

Phase 2

Recruiting

Conditions: Recurrent Extensive Stage Small Cell Lung Carcinoma
Refractory Extensive Stage Small Cell Lung Carcinoma

Interventions: Drug: Talazoparib
Drug: Temozolomide

First Posted Date: 2018-09-14

Last Posted Date: 2025-01-09

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 28

Registration Number: NCT03672773

Locations: 🇺🇸
Ft. Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States
🇺🇸
St. Joseph Heritage Healthcare, Fullerton, California, United States
🇺🇸
CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center, Bakersfield, California, United States

and more 3 locations

Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma

Phase 2

Completed

Conditions: Metastatic Chordoma
Unresectable Chordoma
Chordoma
Locally Advanced Chordoma

Interventions: Biological: Nivolumab
Biological: Relatlimab

First Posted Date: 2018-08-09

Last Posted Date: 2024-04-16

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 10

Registration Number: NCT03623854

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner

Phase 1

Terminated

Conditions: p16 Positive Neoplastic Cells Present
Human Papillomavirus Positive
Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Oropharyngeal Squamous Cell Carcinoma
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

Interventions: Biological: Durvalumab
Procedure: Modified Radical Neck Dissection
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Radiation: Stereotactic Body Radiation Therapy
Procedure: Transoral Robotic Surgery
Biological: Tremelimumab

First Posted Date: 2018-08-07

Last Posted Date: 2023-11-18

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 19

Registration Number: NCT03618134

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Home Terms & Conditions Privacy Policy